Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
8.62
-0.13 (-1.49%)
At close: Sep 11, 2026, 4:00 PM EDT
8.79
+0.17 (1.97%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Immatics Employees
Immatics had 704 employees as of June 30, 2026. The number of employees increased by 58 or 8.98% compared to the same quarter last year.
Employees
704
Change
58
Growth
8.98%
Revenue / Employee
$67,678
Profits / Employee
-$335,192
Market Cap
1.20B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 704 | 58 | 8.98% | 704 | 0 |
| Mar 31, 2026 | 678 | 32 | 4.95% | 678 | 0 |
| Dec 31, 2025 | 711 | 29 | 4.25% | 589 | 122 |
| Sep 30, 2025 | 645 | 73 | 12.76% | 645 | 0 |
| Mar 31, 2025 | 646 | 111 | 20.75% | 646 | 0 |
| Dec 31, 2024 | 682 | 147 | 27.48% | 554 | 128 |
| Sep 30, 2024 | 572 | 139 | 32.10% | 572 | 0 |
| Jun 30, 2024 | 542 | 140 | 34.83% | 542 | 0 |
| Dec 31, 2023 | 535 | 93 | 21.04% | 432 | 103 |
| Sep 30, 2023 | 433 | 45 | 11.60% | 433 | 0 |
| Mar 31, 2023 | 402 | 29 | 7.77% | 402 | 0 |
| Dec 31, 2022 | 442 | 61 | 16.01% | 358 | 84 |
| Jun 30, 2022 | 388 | 57 | 17.22% | 388 | 0 |
| Mar 31, 2022 | 373 | 90 | 31.80% | 373 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Replimune Group | 465 |
| MeiraGTx Holdings | 393 |
| Monte Rosa Therapeutics | 173 |
| MoonLake Immunotherapeutics | 130 |
| ORIC Pharmaceuticals | 111 |
| Odyssey Therapeutics | 100 |
| Alto Neuroscience | 68 |
IMTX News
- 19 days ago - Immatics price target lowered to $17 from $18 at Jefferies - TheFly
- 19 days ago - Immatics announces $150M offering of common stock priced at $8.69 per share - TheFly
- 19 days ago - Immatics Announces $150 Million Underwritten Offering - GlobeNewsWire
- 26 days ago - Immatics Earnings release: Q2 2026 - Filings
- 26 days ago - Immatics reports Q2 EPS (46c), consensus (48c) - TheFly
- 26 days ago - Immatics Announces Second Quarter 2026 Financial Results and Business Update - GlobeNewsWire
- 1 month ago - Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 - GlobeNewsWire
- 3 months ago - Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting - GlobeNewsWire